Clinical Trial Update: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells [Phase 2]

View source ↗

Summary

Phase 2 trial investigating rituximab with combination chemotherapy, G-CSF, and plerixafor for autologous stem cell mobilization in non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (filgrastim)
• Plerixafor (Plerixafor)
• Rituximab (rituximab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02